DOSSIER · 13F-HR · Q1 2026

Boxer Capital Management, LLC

$762M in tracked AUM across 54 positions as of Q1 2026.

BC
CIK 0002018299 · last filed Mar 31, 2026
Total AUM
$762M
as of Q1 2026
Holdings
54
positions
Whale Score
61
61
tracked
Activity
no data
changes this Q
AI Analysis · Q1 2026
Comprehensive Analysis of Boxer Capital Management LLC 13F Filing
Portfolio Overview

Boxer Capital Management LLC manages a concentrated, high-conviction portfolio totaling approximately $266.73 million as of September 30, 2025. The firm has executed a significant strategic pivot over the quarter, evidenced by a 34.3% increase in total portfolio value (rising from $198.66 million) and a substantial turnover in holdings. The portfolio consists of only 26 positions, indicating a ...

Key Holdings

The portfolio is characterized by a "bar-bell" structure, with massive exposure to a few top names and a long tail of smaller positions.

  • Top-Tier Dominance: The two largest positions, Tango Therapeutics Inc (TNGX) and uniQure N.V (QURE), command a combined 48.28% of the total portfolio value. Tango Therapeutics is the single largest holding at $82.08 million (30.77%), while uniQure holds $46.70 million (17.51%). This level of concentration indicates significant conviction in these specific entities.
  • Core Positions: The third-largest holding, Revolution Medicines Inc (RVMD), accounts for 7.00% of the portfolio. Beyond the top three, position sizes drop significantly, generally ranging between 1% and 5%.
  • Long-Tail Exposure: The remainder of the portfolio consists of small-cap and micro-cap biotech stocks, many holding less than 1% of the portfolio weight. This structure suggests the fund uses its top holdings for core alpha generation while using smaller positions for high-risk/high-reward speculative exposure.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
TNGX
TANGO THERAPEUTICS INC
$228M10.9M29.9%
02
KOD
KODIAK SCIENCES INC
$52M1.4M6.8%
03
RVMD
REVOLUTION MEDICINES INC
$49M500K6.4%
04
KYMR
KYMERA THERAPEUTICS INC
$27M329K3.6%
05
CELC
CELCUITY INC
$26M225K3.4%
06
SRZN
SURROZEN INC
$22M766K2.9%
07
ABVX
ABIVAX SA
$22M200K2.9%
08
TERN
TERNS PHARMACEUTICALS INC
$20M375K2.6%
09
PCVX
VAXCYTE INC
$19M325K2.5%
10
CAPR
CAPRICOR THERAPEUTICS INC
$18M590K2.4%

Filing history

2026Q1Mar 31
$762M 66.7%
54 positionsView →
2025Q4Dec 31
$457M 45.6%
45 positionsView →
2025Q3Sep 30
$314M 57.9%
34 positionsView →
2025Q2Jun 30
$199M 40.2%
20 positionsLocked
2025Q1Mar 31
$332M 71.7%
28 positionsLocked
2024Q4Dec 31
$1.2B
60 positionsLocked